Clinical Implications

New Agent Shows Promise in CLL and MCL

Kristie BlumThe New England Journal Watch online of Medicine (NEJM) reported on exciting findings from two studies co-led by researchers at the OSUCCC – James and MD Anderson Cancer Center regarding the targeted experimental drug ibrutinib as an effective treatment for patients with chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). The articles reported the outcome of two phase II clinical trials of ibrutinib, which is showing exceptional effectiveness against both malignancies.

The CLL study co-leader at Ohio State was John C. Byrd, MD, professor and director of the Division of Hematology, and a CLL specialist at the OSUCCC – James. The Ohio State co-leader of the MCL study, which involved 18 sites, was Kristie Blum, MD, associate professor in the Division of Hematology and head of the OSUCCC – James lymphoma program. NEJM first published the two studies together online with an accompanying editorial. The CLL study and the MCL study were then featured in the July 4 and Aug. 8 NEJM print editions, respectively.

Visit the OSUCCC – James CLL Experimental Therapeutics Laboratory.

To refer a patient, please call The James Line New-Patient Referral Center toll free: 1-800-293-5066.

Sign up to receive publications from the OSUCCC – James

Sign Up Now

Meet the Leaders

Leadership & Executive Cabinet at The James

Learn More